The COMMODORE 2 study met its co-primary efficacy endpoints, showing crovalimab achieved disease control in people with paroxysmal nocturnal haemoglobinuria (PNH) who have not been previously treated with
Basel, 2 February 2023 Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division sales increase
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments: Teresa Graham, currently Head of Global Product Strategy
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia
A concrete acceleration towards the decarbonization of the construction industry. Regulatory News: Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) ("Hoffmann Green Cement"